BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zanolimumab: Phase II data

The open-label Phase II Hx-CD4-109 trial in 21 patients showed that 12 weekly IV infusions of 980 mg zanolimumab produced an objective tumor response rate of 24%, including 2 unconfirmed complete responses...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >